QUOTED. Eddie Martucci.
After receiving US FDA clearance for a prescription-only software to treat ADHD and raising total funding of $230m, Akili plans a US launch in 2022 while also targeting other indications for its digital therapeutic EndeavorRx. See what Eddie Martucci, Akili’s CEO, said about it here.
“There is no established playbook for digital therapeutics, so we have been piloting EndeavorRx in the US to gather important feedback from families and physicians.” – Eddie Martucci, CEO, Akili Interactive
- Find out more: Kids, Time To Play Your Medicine: Akili Prepares Launch Of EndeavorRx Video Game For ADHD
Click here for a free trial of Medtech Insight